Medpace Holdings, Inc. MEDP Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total Revenue by Product | ||||||
| AVAI | $141.89M-1.1% | $134.94M-13.8% | $131.53M-22.9% | $133.39M-24.9% | $143.49M-17.8% | |
| Cardiology | $280.14M+45.3% | $254.84M+40.0% | $230.88M+33.9% | $207.35M+19.0% | $192.74M+16.5% | |
| Central Nervous System | $237.35M+1.8% | $239.37M+3.9% | $234.64M+4.9% | $230.98M+8.8% | $233.1M+15.0% | |
| Metabolic | $778.35M+16.8% | $747.59M+14.8% | $719.84M+13.9% | $692.12M+12.3% | $666.52M+11.0% | |
| Oncology | $834.5M+66.3% | $744.96M+62.8% | $618.01M+42.5% | $543.49M+31.9% | $501.92M+27.5% | |
| Other | $406.03M-3.1% | $408.55M-5.3% | $423.48M-3.5% | $424.45M-3.0% | $418.82M-1.7% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Medpace Holdings, Inc. break its business down?
- Medpace Holdings, Inc. (MEDP) reports total revenue by product across 6 parts — AVAI, Cardiology, Central Nervous System, Metabolic and Oncology. Each is extracted from the segment footnotes and tracked over time.
- Where does Medpace Holdings, Inc.'s segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Medpace Holdings, Inc.'s SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
